论文部分内容阅读
目的观察参麦注射液联合GP(吉西他滨+顺铂)方案治疗晚期非小细胞肺癌的疗效和安全性。方法经组织病理学或细胞学证实初治晚期非小细胞肺癌患者60例随机分为对照组和观察组各30例。对照组给予GP方案化疗,观察组在对照组治疗基础上给予参麦注射液60mL/次,1次/d,静脉滴注,连用15d。21d为1个周期,3个周期后比较2组近期疗效、生活质量及不良反应发生情况。结果 2组近期疗效比较差异无统计学意义(P>0.05),观察组生活质量改善优于对照组(P<0.05),观察组血液毒性和消化道反应发生率低于对照组(P<0.05)。结论参麦注射液联合GP方案治疗晚期非小细胞肺癌可降低化疗引起的不良反应,改善患者生活质量。
Objective To observe the efficacy and safety of Shenmai injection combined with GP (gemcitabine + cisplatin) in the treatment of advanced non-small cell lung cancer. Methods Sixty patients with newly diagnosed advanced non-small cell lung cancer confirmed by histopathology or cytology were randomly divided into control group and observation group with 30 cases each. The control group was given GP chemotherapy. The observation group was given Shenmai injection 60mL / time, once a day, intravenously for 15 days. 21d for a period of 3 cycles after 2 groups compared the short-term efficacy, quality of life and adverse reactions. Results There was no significant difference in short-term curative effect between the two groups (P> 0.05). The improvement of quality of life in the observation group was better than that of the control group (P <0.05), and the incidence of hematotoxicity and gastrointestinal reaction in the observation group was lower than that of the control group ). Conclusion Shenmai injection combined with GP regimen in the treatment of advanced non-small cell lung cancer can reduce chemotherapy-induced adverse reactions and improve the quality of life of patients.